Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Francois Guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino A de Souza; Jeffrey H Lipton; Andreas Hochhaus

doi:10.1182/blood-2006-09-046839

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Identifier:nobleid.org/w1/20260515/BBAEEFD8

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/BBAEEFD8.svg?ark=w1%2F20260515%2FBBAEEFD8)](https://nobleid.org/work/w1/20260515/BBAEEFD8)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Identifier:nobleid.org/w1/20260515/BBAEEFD8

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/BBAEEFD8.svg?ark=w1%2F20260515%2FBBAEEFD8)](https://nobleid.org/work/w1/20260515/BBAEEFD8)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work